Key points are not available for this paper at this time.
To compare the safety and tolerability of fenebrutinib in people with multiple sclerosis (MS) and those with autoimmune indications (AIs).
Oh et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: